No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study

BACKGROUND: Roflumilast is an oral, selective phosphodiesterase 4 inhibitor with anti-inflammatory effects in chronic obstructive pulmonary disease (COPD). The addition of roflumilast to long-acting bronchodilators improves lung function in patients with moderate-to-severe COPD. The present study in...

Descripción completa

Detalles Bibliográficos
Autores principales: de Mey, Christian, Nassr, Nassr, Lahu, Gezim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127977/
https://www.ncbi.nlm.nih.gov/pubmed/21631929
http://dx.doi.org/10.1186/1472-6904-11-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127977/
https://www.ncbi.nlm.nih.gov/pubmed/21631929
http://dx.doi.org/10.1186/1472-6904-11-7

Ejemplares similares